

NOTE: ▼ Limited trial; not open ETCTN-wide

## ETCTN Solid Tumors- Dose Escalation Only (Disease-Specific Expansion) Trials (Open as of 11/10/2025)

<b>Protocol Number</b>	Phase	Protocol Title
10276	1/11	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
10358	I/Ib	Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
10355	I	A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies
10509	I	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
10579	I	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors
10554	I	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression